市场调查报告书
商品编码
1467688
2024-2032年婴儿痉挛治疗市场依治疗类别、药物类型(氨己烯酸、促肾上腺皮质激素等)、剂量、给药途径、配销通路、最终用户和地区Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others ), Dosage, Route of Administration, Distribution Channel, End User, and Region 2024-2032 |
IMARC Group年,全球婴儿痉挛症治疗市场规模达36亿美元。婴儿癫痫发作的盛行率不断上升、大众健康意识的提高导致早期诊断、产品批准数量的增加和强大的管道药物的存在是推动市场的一些关键因素。
婴儿痉挛疗法是指用于治疗幼儿癫痫发作或癫痫症候群的治疗程序,幼儿通常年龄在四个月到一岁之间。痉挛发作的特征是身体突然僵硬,手臂、腿和头部向前弯曲,背部拱起,以及短暂而微妙的癫痫发作。婴儿痉挛症可由脑肿瘤、出生损伤、脑部感染和基因改变引起。针对婴儿垃圾邮件有多种治疗选择,包括类固醇、促肾上腺皮质激素注射凝胶和糖皮质激素的荷尔蒙疗法以及抗癫痫药物。如果在痉挛发生后三週内实施,婴儿痉挛症治疗更有可能提供持续的结果,治疗可以透过单一疗法或合併疗法来完成。婴儿痉挛症可透过身体检查、神经系统检查、脑部 MRI 以及血液和尿液检查来诊断。
新生儿中婴儿痉挛症盛行率的增加是推动市场成长的重要因素。这可以归因于全球出生率的大幅上升。与此一致的是,越来越多的产品批准和强大的管道药物的存在正在对市场产生积极影响。婴儿痉挛症治疗的持续技术进步,例如引入用于检测癫痫发作并提醒护理人员的癫痫警报装置,正在为市场提供动力。此外,人们对早期诊断和治疗的广泛认识正在提高婴儿痉挛症药物的渗透率,从而推动市场成长。然而,各种因素,例如治疗成功率较低、治疗成本较高、药物审批的严格规定以及未确诊患者数量的增加,正在阻碍婴儿痉挛症治疗市场的成长。相反,一些国家的政府和私人组织为提高人们对医疗状况的认识而采取的有利倡议和计划正在创造积极的市场前景。主要市场参与者所进行的广泛研发(R&D)活动进一步推动了市场的发展,这些活动专注于开发成功率更高的创新药物。影响市场的其他一些因素包括不断扩大的医疗保健支出、不断增加的合作、伙伴关係和併购 (M&A)、快速城市化以及可支配收入水平的提高。
The global infantile spasms therapeutics market size reached US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.
Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.
The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.
IMARC Group provides an analysis of the key trends in each segment of the global infantile spasms therapeutics market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on therapeutic class, drug type, dosage, route of administration, distribution channel, and end user.
Anticonvulsants
Corticosteroids
Others
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the therapeutic class. This includes anticonvulsants, corticosteroids, and others. According to the report, anticonvulsants represented the largest segment.
Vigabatrin
Adrenocorticotropic Hormone
Others (Phase III)
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the drug type. This includes vigabatrin, adrenocorticotropic hormone, and others (phase III). According to the report, adrenocorticotropic hormone represented the largest segment.
Solid
Liquid
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the dosage. This includes solid and liquid. According to the report, liquid represented the largest segment.
Oral
Parenteral
Others
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the route of administration. This includes oral, parenteral, and others. According to the report, parenteral represented the largest segment.
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the distribution channel. This includes hospital pharmacy, retail pharmacy, and online pharmacy. According to the report, hospital pharmacy represented the largest segment.
Hospitals
Clinics
Others
A detailed breakup and analysis of the infantile spasms therapeutics market based on the end user has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.
The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.